stockportfolio.pro
Option Care Health, Inc. (OPCH)
Healthcare · Medical Care Facilities · NasdaqGS
Option Care Health, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $935.59M | $1.83B | $1.94B | $2.31B | $3.03B | $3.44B | $3.94B | $4.30B | $5.00B | $5.65B |
| Gross profit | $262.08M | $446.00M | $422.21M | $513.00M | $682.26M | $779.61M | $866.92M | $981.22M | $1.01B | $1.09B |
| Net income | $-42.77M | $3.88M | $-6.12M | $-75.92M | $-8.08M | $139.90M | $150.56M | $267.09M | $211.82M | $207.59M |
| Net margin | -4.6% | 0.2% | -0.3% | -3.3% | -0.3% | 4.1% | 3.8% | 6.2% | 4.2% | 3.7% |
Source: Option Care Health, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of Option Care Health, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track OPCH in your portfolio →
About Option Care Health, Inc.
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.
Option Care Health, Inc. — frequently asked questions
What is Option Care Health, Inc.'s revenue?
Option Care Health, Inc. (OPCH) reported revenue of $5.65B for fiscal year 2025, up 13.0% from the prior year, according to its SEC filings.
Is Option Care Health, Inc. profitable?
Yes. OPCH earned net income of $207.59M in fiscal 2025, a net margin of 3.7%.
What is OPCH's P/E ratio?
Option Care Health, Inc. trades at a price-to-earnings ratio of about 16.8 based on the latest data in our nightly-refreshed cache.
How fast is Option Care Health, Inc. growing?
OPCH's revenue grew at roughly 13.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Option Care Health, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.